Finance

Galderma Slumps After FDA Turns Down Botox Rival Relfydess

Galderma Group AG shares slumped the most in more than a year after the US Food and Drug Administration turned down the Swiss dermatology firm’s rival Botox treatment Relfydess.

BL Bloomberg MarketsUpdated 3h ago1 min read

🤖 AI AI Summary & AI Analysis

⟳ AI is analyzing this article…

Galderma Group AG shares slumped the most in more than a year after the US Food and Drug Administration turned down the Swiss dermatology firm’s rival Botox treatment Relfydess.

Full article body is being fetched in the background. Refresh in a moment to see the complete paragraphs. For now this page shows a summary and AI analysis.